Dialysis News and Research

Latest Dialysis News and Research

Lilly, Boehringer Ingelheim to present new data from diabetes portfolio at ADA scientific sessions

Boehringer Ingelheim and Lilly will present the latest data from their diabetes portfolio at the 71st American Diabetes Association (ADA) Scientific Sessions in San Diego on June 25-29.

21 Jun 2011

Boston Scientific to launch Mustang PTA Balloon Catheter worldwide

Boston Scientific Corporation today announced the global launch of its Mustang™ PTA Balloon Catheter, a highly deliverable 0.035 inch percutaneous transluminal angioplasty (PTA) catheter designed for a wide range of peripheral angioplasty procedures. The Company plans to launch the product immediately in the U.S., Europe and other international markets.

20 Jun 2011

Concert to advance CTP-499, C-21191 into Phase 2 trials for diabetic nephropathy and spasticity

Concert Pharmaceuticals, Inc. announced today the advancement of two programs from its DCE Platform. CTP-499 is progressing into Phase 2 clinical trials for diabetic nephropathy and C-21191 has been selected as a lead candidate for spasticity.

20 Jun 2011

Celgene announces data from REVLIMID plus rituximab Phase II study on malignant lymphomas

Celgene International Sàrl announced that clinical data from a Phase II study, conducted by investigators from the MD Anderson Cancer Center in Houston, TX, evaluating the combination regimen of REVLIMID plus rituximab (R2) in untreated, advanced stage, indolent B-cell non-Hodgkin's lymphomas, were presented at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland.

18 Jun 2011

Celgene, GELA to conduct REVLIMID/rituximab combination study on newly diagnosed FL

Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Celgene International Sarl today announced a collaboration to conduct an international randomized study to evaluate the therapeutic potential of the REVLIMID/rituximab combination regimen (R2) in patients with newly diagnosed follicular lymphoma.

17 Jun 2011

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

Celgene International Sàrl announced that clinical data from two studies evaluating the use of REVLIMID® (lenalidomide) with standard R-CHOP chemotherapy in patients with untreated diffuse large B cell (DLBCL) or grade 3 follicular lymphoma were presented at the 11th International Conference on Malignant Lymphoma in Lugano, Switzerland.

17 Jun 2011

Phosphate regulating hormone associated with increased risk of kidney failure and death among CKD patients

A high level of a hormone that regulates phosphate is associated with an increased risk of kidney failure and death among chronic kidney disease (CKD) patients, according to a recent study led by researchers at the University of Miami and funded by the National Institute of Diabetes and Digestive Diseases and Kidney Diseases (NIDDK) at the National Institutes of Health.

16 Jun 2011

Overactive mTOR can result in serious disruption of kidney filter in diabetes patients

Diabetes mellitus is one of the most common secondary diseases in modern society. And because it is on the rise, it is also one of the greatest challenges facing medicine today. Diabetes patients do not die as a direct result of the increase in blood sugar, but from the long-term complications of their disease, in which the increase in blood sugar causes damage to blood vessels and organs.

15 Jun 2011

New ultrasound technique can measure blood pressure at many points in the body

Researchers at Eindhoven University of Technology, together with the Italian company Esaote, have developed a new technique to measure the blood pressure.

15 Jun 2011

CorMedix completes enrollment in CRMD001 Phase II trial for treatment of acute kidney injury

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, announced it successfully completed patient enrollment in its phase II Contrast-Induced Acute Kidney Injury study with its oral drug candidate CRMD001.

14 Jun 2011

Final data from Alexion's Soliris Phase 2 studies on aHUS presented at EHA 2011

Alexion Pharmaceuticals, Inc. today announced the presentation of final data from the two Phase 2 studies of Soliris as a treatment for patients with atypical hemolytic uremic syndrome.

13 Jun 2011

Viewpoints: Health law's latest day in court; Obama's "abdication" on Medicare; Blue Shield profits vs. premiums

Provisions of the federal Affordable Care Act, also known as ObamaCare, "may violate the constitution of Ayn Rand, but they do not violate the Constitution of the United States," acting solicitor general Neal Kumar Katyal told a three-judge panel of the 11th Circuit Court of Appeals Wednesday. Conversely, attorney Paul Clement, representing Georgia and 25 other states, framed the issue of mandated purchase of health insurance as an issue of liberty.

10 Jun 2011

ICU patients should wait a week before receiving intravenous feeding: New study

Patients in the intensive care unit who do not tolerate adequate nutrition from tube feeding should wait a week before receiving intravenous (IV) feeding because, compared with early IV feeding, it enhances recovery from critical illness.

8 Jun 2011

Millennium reports results from two VELCADE based combination studies against multiple myeloma

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today reported results from two studies of VELCADE (bortezomib) for Injection based combinations in patients with relapsed or refractory multiple myeloma (MM).

8 Jun 2011

Promising results from KAI-4169 program for CKD-MBD presented at ENDO 2011

KAI Pharmaceuticals, Inc., a privately held drug discovery and development company, today announced clinical and preclinical data from its lead program, KAI-4169, at the Endocrine Society's 93rd Annual Meeting (ENDO 2011) taking place in Boston, June 4-7, 2011. KAI-4169 is a novel pharmaceutical agent being developed for the treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).

7 Jun 2011

Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

Celgene International Sàrl today announced results from a phase II investigator initiated study of REVLIMID (lenalidomide) in combination with Avastin (bevacizumab), docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer were presented at the 2011 American Society of Clinical Oncology Annual Meeting in Chicago, Ill.

6 Jun 2011

New E. coli outbreak alarms Europe

An Escherichia coli (E. coli) outbreak of disease in Germany has left 22 people dead and it is alarming populations across Europe.

5 Jun 2011

Alexion's sBLA for Soliris receives FDA Priority Review designation to treat aHUS

Alexion Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration has granted the Company's request for Priority Review of its supplemental Biologics License Application for Soliris as a treatment for patients with atypical Hemolytic Uremic Syndrome.

1 Jun 2011

HbA1c glucose monitoring test not effective for diagnosing diabetes patients with kidney failure

The gold standard long-term glucose monitoring test for patients with diabetes proved to be of limited value in dialysis patients, according to a new study at Wake Forest Baptist Medical Center.

1 Jun 2011

Eculizumab effective for treating hemolytic-uremic syndrome from EHEC

In the online version of the New England Journal of Medicine, physicians and scientists in Heidelberg, Montreal, and Paris reported on the successful treatment of three young children who were suffering from a severe hemolytic-uremic syndrome after an infection with enterohemorrhagic Escherichia coli.

1 Jun 2011

Dialysis News and Research

Latest Dialysis News and Research

Lilly, Boehringer Ingelheim to present new data from diabetes portfolio at ADA scientific sessions

Boston Scientific to launch Mustang PTA Balloon Catheter worldwide

Concert to advance CTP-499, C-21191 into Phase 2 trials for diabetic nephropathy and spasticity

Celgene announces data from REVLIMID plus rituximab Phase II study on malignant lymphomas

Celgene, GELA to conduct REVLIMID/rituximab combination study on newly diagnosed FL

REVLIMID-R-CHOP Phase I/II data in untreated DLBCL presented at malignant lymphoma conference

Phosphate regulating hormone associated with increased risk of kidney failure and death among CKD patients

Overactive mTOR can result in serious disruption of kidney filter in diabetes patients

New ultrasound technique can measure blood pressure at many points in the body

CorMedix completes enrollment in CRMD001 Phase II trial for treatment of acute kidney injury

Final data from Alexion's Soliris Phase 2 studies on aHUS presented at EHA 2011

Viewpoints: Health law's latest day in court; Obama's "abdication" on Medicare; Blue Shield profits vs. premiums

ICU patients should wait a week before receiving intravenous feeding: New study

Millennium reports results from two VELCADE based combination studies against multiple myeloma

Promising results from KAI-4169 program for CKD-MBD presented at ENDO 2011

Celgene announces results of REVLIMID, docetaxel/prednisone phase II combination study on mCRPC

New E. coli outbreak alarms Europe

Alexion's sBLA for Soliris receives FDA Priority Review designation to treat aHUS

HbA1c glucose monitoring test not effective for diagnosing diabetes patients with kidney failure

Eculizumab effective for treating hemolytic-uremic syndrome from EHEC

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Dialysis News and Research

Latest Dialysis News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in